ReviewInternational journal of molecular sciences2021
Specialized Pro-Resolving Lipid Mediators: The Future of Chronic Pain Therapy?
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Tr14 gel compared to diclofenac gel after acute unilateral ankle sprain: an Individual Patient Data (IPD) meta-analysis of two multi-center trials.BMC musculoskeletal disorders · 2026Pooled it
- Lipid metabolic regulation of neuroinflammation in Alzheimer's disease.Frontiers in immunology · 2026Review
- Beyond Symptom Suppression: The Multitargeted Reversal of Chronic Pain by Maresin1.Drug design, development and therapy · 2026Review
- Association Between the Triglyceride-Glucose Index and Incident Chronic Severe Pain in Middle-Aged and Older Chinese Adults: A Nationwide Cohort Study.Pain research & management · 2026Article
- ALX/FPR2 Receptor Activation by Inflammatory (fMLFII) and Pro-resolving (LXAACS physical chemistry Au · 2025Article
- Dysregulation of Arachidonic Acid Metabolism Drives Inflammatory Lipid Production in Localized Provoked Vulvodynia.Nutrients · 2025Article
- Efficient One-Step Production of 7S,17S- and 10S,17S-Dihydroxydocosahexaenoic Acids by a Double-Oxygenating 15S-Lipoxygenase From Chlamydomonas incerta.Biotechnology and bioengineering · 2025Article
- Endometriosis: An Immunologist's Perspective.International journal of molecular sciences · 2025Review
- Review
- The mechanisms of specialized pro-resolving mediators in pain relief: neuro-immune and neuroglial regulations.Frontiers in immunology · 2025Review
- Physiotherapy Reduces Pain and Alters Fatty Acid Biomarkers in Women with Chronic Non-Specific Low Back Pain.International journal of women's health · 2025Article
- The Causal Relationship Between Immune Cells and Neuropathic Pain: A Two-Sample Mendelian Randomization Study Based on Genome-Wide Association Analysis.Journal of pain research · 2025Article
- Review
- The Impact of Nutrition on Pain: A Narrative Review of Recent Literature.Current pain and headache reports · 2024Review
- Nutritional Strategies for Chronic Craniofacial Pain and Temporomandibular Disorders: Current Clinical and Preclinical Insights.Nutrients · 2024Review
- Exploring PGE2 and LXA4 Levels in Migraine Patients: The Potential of LXA4-Based Therapies.Diagnostics (Basel, Switzerland) · 2024Article
- Neuroimmunological effects of omega-3 fatty acids on migraine: a review.Frontiers in neurology · 2024Review
- Pain-resolving immune mechanisms in neuropathic pain.Nature reviews. Neurology · 2023Review
- Possibility of averting cytokine storm in SARS-COV 2 patients using specialized pro-resolving lipid mediators.Biochemical pharmacology · 2023Review
- Specialized Pro-Resolving Mediators as Resolution Pharmacology for the Control of Pain and Itch.Annual review of pharmacology and toxicology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 4 countries.
Funding
Abstract
Chronic pain (CP) is a severe clinical entity with devastating physical and emotional consequences for patients, which can occur in a myriad of diseases. Often, conventional treatment approaches appear to be insufficient for its management. Moreover, considering the adverse effects of traditional analgesic treatments, specialized pro-resolving lipid mediators (SPMs) have emerged as a promising alternative for CP. These include various bioactive molecules such as resolvins, maresins, and protectins, derived from ω-3 polyunsaturated fatty acids (PUFAs); and lipoxins, produced from ω-6 PUFAs. Indeed, SPMs have been demonstrated to play a central role in the regulation and resolution of the inflammation associated with CP. Furthermore, these molecules can modulate neuroinflammation and thus inhibit central and peripheral sensitizations, as well as long-term potentiation, via immunomodulation and regulation of nociceptor activity and neuronal pathways. In this context, preclinical and clinical studies have evidenced that the use of SPMs is beneficial in CP-related disorders, including rheumatic diseases, migraine, neuropathies, and others. This review integrates current preclinical and clinical knowledge on the role of SPMs as a potential therapeutic tool for the management of patients with CP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.